hydralazine has been researched along with losartan potassium in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisher, JW; Malgor, LA | 1 |
| Chang, SL; Draksharapu, A; Mak, RH; Pak, YK | 1 |
| Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME | 1 |
| Balanos, GM; Dorrington, KL; Fatemian, M; Liu, C; Robbins, PA; Smith, TG | 1 |
| Adhyaru, B; Raj, L | 1 |
1 review(s) available for hydralazine and losartan potassium
| Article | Year |
|---|---|
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
Topics: Adrenergic beta-Antagonists; American Heart Association; Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Atrial Natriuretic Factor; Benzazepines; Biphenyl Compounds; Calcium Channel Blockers; Cardiology; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Drug Combinations; Erythropoietin; Evidence-Based Medicine; Fumarates; Heart Failure; Hematinics; Humans; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Societies, Medical; Stroke Volume; Tetrazoles; United States; Valsartan; Vasodilator Agents | 2016 |
4 other study(ies) available for hydralazine and losartan potassium
| Article | Year |
|---|---|
Antagonism of angiotensin by hydralazine on renal blood flow and erythropoietin production.
Topics: Angiotensin II; Animals; Blood Flow Velocity; Blood Pressure; Dogs; Drug Synergism; Erythropoietin; Female; Hematocrit; Hydralazine; Kidney; Male; Polycythemia; Renal Artery | 1969 |
Gene expression in uremic left ventricular hypertrophy: effects of hypertension and anemia.
Topics: Actins; Anemia; Animals; Atrial Natriuretic Factor; Erythropoietin; Gene Expression; Heart Ventricles; Hydralazine; Hypertension; Hypertrophy, Left Ventricular; Male; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1; Uremia | 2004 |
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Disease Models, Animal; Drug Therapy, Combination; Erythropoietin; Hydralazine; Hydrochlorothiazide; Hypertension; Kidney; Kidney Failure, Chronic; Losartan; Nephrectomy; Rats; Rats, Wistar; Recombinant Proteins; Renin-Angiotensin System; Reserpine; Time Factors; Uremia | 2006 |
Effects of hydralazine on the pulmonary vasculature and respiratory control in humans.
Topics: Adult; Algorithms; Blood Pressure; Cardiac Output; Erythropoietin; Female; Gene Expression; Heart Rate; Humans; Hydralazine; Hypoxia-Inducible Factor 1; Male; Pulmonary Circulation; Respiratory Mechanics; Vascular Endothelial Growth Factor A; Vasodilator Agents | 2008 |